Editas Medicine Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 87

Employees

  • Stock Symbol
  • EDIT

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.64
  • (As of Friday Closing)

Editas Medicine General Information

Description

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Contact Information

Formerly Known As
Gengine
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 11 Hurley Street
  • Cambridge, MA 02141
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 11 Hurley Street
  • Cambridge, MA 02141
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Editas Medicine Stock Performance

As of 20-Nov-2026, Editas Medicine’s stock price is $1.64. Its current market cap is $253M with 154M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.64 $1.71 $1.63 - $3.94 $253M 154M 2.62M -$0.60

Editas Medicine Financials Summary

As of 30-Sep-2026, Editas Medicine has a trailing 12-month revenue of $49.8M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 198,567 54,122 (121,764) 512,348
Revenue 49,827 40,520 32,314 78,123
EBITDA (73,607) (156,899) (245,346) (164,721)
Net Income (72,225) (160,060) (237,093) (153,219)
Total Assets 219,412 186,534 341,589 499,153
Total Debt 13,941 18,102 35,032 36,536
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Editas Medicine Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Editas Medicine‘s full profile, request access.

Request a free trial

Editas Medicine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Editas Medicine‘s full profile, request access.

Request a free trial

Editas Medicine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomi
Drug Discovery
Cambridge, MA
87 As of 2026

Cambridge, MA
 

Zug, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Editas Medicine Competitors (52)

One of Editas Medicine’s 52 competitors is Intellia Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intellia Therapeutics Formerly VC-backed Cambridge, MA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Caribou Biosciences Formerly VC-backed Berkeley, CA
Verve Therapeutics Formerly VC-backed Boston, MA
EdiGene Venture Capital-Backed Beijing, China
You’re viewing 5 of 52 competitors. Get the full list »

Editas Medicine Patents

Editas Medicine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260242779-A1 Crispr-related methods and compositions targeting low-density lipoprotein receptor (ldlr) Pending 15-Jan-2025
WO-2026156101-A2 Crispr-related methods and compositions targeting low-density lipoprotein receptor (ldlr) Pending 15-Jan-2025
WO-2026156101-A3 Crispr-related methods and compositions targeting low-density lipoprotein receptor (ldlr) Pending 15-Jan-2025
WO-2026102260-A1 Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3) Pending 08-Nov-2024
WO-2026064475-A1 Crispr cas-related methods and compositions targeting ptpn2 expression Pending 18-Sep-2024 C12N15/1137
To view Editas Medicine’s complete patent history, request access »

Editas Medicine Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Editas Medicine Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Editas Medicine‘s full profile, request access.

Request a free trial

Editas Medicine Acquisitions (1)

Editas Medicine’s most recent deal was a Merger/Acquisition with i2 Pharmaceuticals for . The deal was made on 22-Jan-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
i2 Pharmaceuticals 22-Jan-2018 Merger/Acquisition Drug Discovery
To view Editas Medicine’s complete acquisitions history, request access »

Editas Medicine ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

22.6 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Editas Medicine’s complete esg history, request access »

Editas Medicine FAQs

  • When was Editas Medicine founded?

    Editas Medicine was founded in 2013.

  • Where is Editas Medicine headquartered?

    Editas Medicine is headquartered in Cambridge, MA.

  • What is the size of Editas Medicine?

    Editas Medicine has 87 total employees.

  • What industry is Editas Medicine in?

    Editas Medicine’s primary industry is Drug Discovery.

  • Is Editas Medicine a private or public company?

    Editas Medicine is a Public company.

  • What is Editas Medicine’s stock symbol?

    The ticker symbol for Editas Medicine is EDIT.

  • What is the current stock price of Editas Medicine?

    As of 20-Nov-2026 the stock price of Editas Medicine is $1.64.

  • What is the current market cap of Editas Medicine?

    The current market capitalization of Editas Medicine is $253M.

  • What is Editas Medicine’s current revenue?

    The trailing twelve month revenue for Editas Medicine is $49.8M.

  • Who are Editas Medicine’s competitors?

    Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, Verve Therapeutics, and EdiGene are some of the 52 competitors of Editas Medicine.

  • What is Editas Medicine’s annual earnings per share (EPS)?

    Editas Medicine’s EPS for 12 months was -$0.60.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process